Linked Life Data

20370456

Source:http://linkedlifedata.com/resource/pubmed/id/20370456

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20370456rdf:typepubmed:Citationlld:pubmed
pubmed-article:20370456lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0022661lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0019721lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0031437lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0449438lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:20370456lifeskim:mentionsumls-concept:C0024284lld:lifeskim
pubmed-article:20370456pubmed:issue3lld:pubmed
pubmed-article:20370456pubmed:dateCreated2010-4-7lld:pubmed
pubmed-article:20370456pubmed:abstractTextPatients with pre-transplantation high levels of panel reactive antibody (PRA) have an increased risk of graft failure, and renal transplantation in sensitized patients remains a highly significant challenge worldwide. The influence of anti-human leukocyte antigen (HLA) antibodies on the development of rejection episodes depends on patient-specific clinical factors and differs from patient to patient. The HLA typing of the recipient might influence the development of anti-HLA antibodies. Some HLA antigens appear to be more immunogenic than others. The aim of this study is to demonstrate the distribution of HLA phenotypes in PRA-positive and PRA-negative end-stage renal disease (ESRD) patients on the basis of having sensitizing events or not. Our study included 642 (mean age: 41.54; female/male: 310/332) ESRD patients preparing for the first transplantation and who are on the cadaveric kidney transplantation waiting list of Istanbul Medical Faculty in 2008-2009. Class I HLA-A,B typing was performed by complement-dependent cytotoxicity (CDC) method, whereas class II HLA-DRB1 typing was performed by low-resolution polymerase chain reaction (PCR)-sequence-specific primer (SSP). All serum samples were screened for the presence of IgG type of anti-HLA class I- and II-specific antibodies by enzyme-linked-immunosorbent assay (ELISA). PRA-negative group consisted of 558 (86.9%) and PRA-positive group included 84 (13.1%) patients. We have found statistically significant frequency of HLA-A3 (p=0.018), HLA-A66 (p=0.04), and HLA-B18 (p=0.006) antigens in PRA-positive patients and DRB1*07 (p=0.02) having the highest frequency in patients with sensitizing event history but no anti-HLA development suggesting that DRB1*07 might be associated with low risk of anti-HLA antibody formation.lld:pubmed
pubmed-article:20370456pubmed:languageenglld:pubmed
pubmed-article:20370456pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20370456pubmed:citationSubsetIMlld:pubmed
pubmed-article:20370456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20370456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20370456pubmed:statusMEDLINElld:pubmed
pubmed-article:20370456pubmed:monthJanlld:pubmed
pubmed-article:20370456pubmed:issn1525-6049lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:YaziciHalilHlld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:TurkmenAydinAlld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:SeverMehmet...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:OguzFatma...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:OnalAyse...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:KarahanGonca...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:KekikCigdemClld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:AydinAli...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:EldegezUlugUlld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:CarinMahmut...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:Bakkalo?luHüs...lld:pubmed
pubmed-article:20370456pubmed:authorpubmed-author:Cali?kanYa?ar...lld:pubmed
pubmed-article:20370456pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20370456pubmed:volume32lld:pubmed
pubmed-article:20370456pubmed:ownerNLMlld:pubmed
pubmed-article:20370456pubmed:authorsCompleteYlld:pubmed
pubmed-article:20370456pubmed:pagination380-3lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:meshHeadingpubmed-meshheading:20370456...lld:pubmed
pubmed-article:20370456pubmed:year2010lld:pubmed
pubmed-article:20370456pubmed:articleTitleAssociation of HLA phenotypes of end-stage renal disease patients preparing for first transplantation with anti-HLA antibody status.lld:pubmed
pubmed-article:20370456pubmed:affiliationDepartment of Medical Biology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey. gonca.karahan@gmail.comlld:pubmed
pubmed-article:20370456pubmed:publicationTypeJournal Articlelld:pubmed